预约演示

Ascendis sells Japanese rights to Skytrofa and two other hormone drugs for $70M upfront

2023-11-29

交易

上市批准引进/卖出

Teijin Pharma now has the rights to commercialize Skytrofa in the country along with TransCon PTH and TransCon CNP.

Teijin Pharmama has pocketed $70 million in exchanSkytrofahe Japanese rights to the FDA-approved long-acting growth hormone Skytrofa and two other hormone drugs.

Ascendis Pharmaont payment, Teijin Pharma has pledged up to $175 million in development and regulatory milestones as well asSkytrofanal commercial milestones and royalties that could reach up to the mid-20s per cent. In exchange, the Tokyo-based company has secured the rights to use Skytrofa—also known as TransCon hGH—along with TransCon PTH and TransCon CNP to treat endocrinology rare disease in Japan.

“Ascendis has leveraged its Teijin PharmaansCon technology platform to create a suite of highly differentiated product candidates with best-in-class potential that complement our existing pharmaceutical portfolio,” Teijin CEO Akimoto Uchikawa said in the Nov. 29 release.Skytrofa TransCon TransCon hGH TransCon TransCon PTH TransCon TransCon CNP

SAscendisbagged FDA approval in 2021 for children aged one year and older with growth hormone deficiency who weigh at least 25.4 pounds. It marked the first approved pediatric therapy for the condition that can be tTeijinnce weekly as opposed to the standard-of-care daily somatropin.

Skytrofa also seFDAed EU approval but has yet to be submitted in Japan. It meangrowth hormone deficiency rights to commercialize the drug in the country along with TransCon PTH and TransCon CNP.somatropin

Skytrofa brought in third-quarter revenue of 47 million euros ($52 million) to AscendiTeijinding the Danish drugmaker to increase its full-year expectations for the hormone therapy from the 165–170 million euros range ($181–$187 million) to 170-175 million euros ($187–$192 million).

TransCon PTH hasn’t had an easy ride with regulators. The FDA issued a manufactAscendislated complete response letter for the company’s adult hypoparathyroidism approval application back in May, although Ascendis resubmitted the request earlier this month on the back of a meeting with the agency. The drug secured an approval in the EU last week, where it will be marketed as Yorvipath.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构